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Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and clonal evolution. The molecular profile of CRC is routinely assessed in surgical or bioptic samples 1 . Genotyping of CRC tissue has inherent limitations; a tissue sample represents a single snapshot in time, and it is subjected to spatial selection bias owing to tumor heterogeneity. Repeated tissue samples are difficult to obtain and cannot be used for dynamic monitoring of disease progression and response to therapy. We exploited circulating tumor DNA (ctDNA) to genotype colorectal tumors and track clonal evolution during treatment with the epidermal growth factor receptor (EGFR)-specific antibodies cetuximab or panitumumab. We identified alterations in ctDNA of patients with primary or acquired resistance to EGFR blockade in the following genes: KRAS, NRAS, MET, ERBB2, FLT3, EGFR and MAP2K1. Mutated KRAS clones, which emerge in blood during EGFR blockade, decline upon withdrawal of EGFR-specific antibodies, indicating that clonal evolution continues beyond clinical progression. Pharmacogenomic analysis of CRC cells that had acquired resistance to cetuximab reveals that upon antibody withdrawal KRAS clones decay, whereas the population regains drug sensitivity. ctDNA profiles of individuals who benefit from multiple challenges with anti-EGFR antibodies exhibit pulsatile levels of mutant KRAS. These results indicate that the CRC genome adapts dynamically to intermittent drug schedules and provide a molecular explanation for the efficacy of rechallenge therapies based on EGFR blockade.
An improved understanding of the underlying molecular pathology of CRC has enabled tailored treatment regimens and helped optimize outcomes. CRC tissue is currently used to define the molecular status of clinically relevant genes. For example, oncogenic mutations in KRAS and NRAS, which occur in about 55% of CRC patients and predict a lack of response to the EGFR-targeted monoclonal antibodies cetuximab and panitumumab 2 , are routinely assessed in tumor specimens. Mutations in BRAF are also associated with a lack of response to EGFR blockade, and they are frequently evaluated in CRC patients 3 . Furthermore, in colorectal tumors lacking RAS pathway mutations, MET or ERBB2 gene amplifications are being explored as biomarkers of response to drugs inhibiting the corresponding oncoproteins [4] [5] [6] .
Tumor tissue genotyping has inherent limitations. It has been shown that the genomic profiles of primary tumors and metastases are not always concordant owing to the intrinsic molecular heterogeneity of cancer [7] [8] [9] . Furthermore, commonly used chemotherapeutic agents as well as targeted drugs can alter the tumor molecular landscape 8 . To account for these spatial and temporal changes, the genomic profiles of individuals with CRC should be evaluated repeatedly during the course of therapy. Several reasons prevent the repeated use of tissue biopsies, including the inherent risk of complications associated with these procedures 10 . Moreover, biopsy samples are often limited and tissue processing might delay the initiation of treatment. The analysis of ctDNA, using a procedure known as liquid biopsy [11] [12] [13] [14] [15] [16] , has been proposed as a way to overcome the restrictions of tumor tissue genotyping. It has been postulated that liquid biopsies may be used to monitor both intrinsic resistance due to primary tumor heterogeneity, as well as to dynamically track the acquisition of secondary resistance to therapy through the selection of additional molecular alterations.
Here we used blood-based molecular profiles to identify actionable targets, monitor drug resistance, and track tumor dynamics in CRC patients. To analyze ctDNA, we applied Droplet Digital PCR Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients l e t t e r S 7 9 6 VOLUME 21 | NUMBER 7 | JULY 2015 nature medicine (ddPCR) 17, 18 and BEAMing 19 . Both technologies are based on microcompartmentalization of the PCR, and both can detect mutant alleles with high sensitivity (0.01-0.001%) 20 . First, we evaluated whether the genotype of RAS pathway genes of clinical relevance could be determined in ctDNA. We selected a total of 100 CRC cases (Supplementary Table 1, Supplementary Fig. 1 and Supplementary Data) for which we collected matched pairs of tissue and blood samples. We used ddPCR to interrogate the mutational status of KRAS, BRAF and NRAS in plasma samples without prior knowledge of the tissue genotype. In 97/100 cases (97%) determinations of 'RAS pathway mutations' were concordant between tissue and blood ( Supplementary Fig. 1a and Supplementary Table 2) . Two of the discordant cases (ONCG-CRC21 and ONCG-CRC55) were from subjects with low tumor burden (lymph node-limited disease or lesions <1.5 cm in size) as assessed by imaging (data not shown).
In eight cases, plasma analysis revealed mutations which were not detected in the matched tissue, thus denoting that the blood more comprehensively captures intra-patient disease heterogeneity ( Supplementary Fig. 1a and Supplementary Table 2 ). The mutational status did not correlate with the levels of circulating free DNA (genome equivalents, GE) indicating that the genotype does not overtly affect release of tumor DNA in the blood (Supplementary Fig. 1b ).
At present, even when KRAS-and NRASmutant CRCs are excluded from treatment, only 20% of subjects benefit from monotherapy with EGFR-targeted agents 21, 22 . Using a cohort of ten individuals who received EGFR-specific antibody regimens without achieving clinical benefit, we asked whether the molecular basis of primary resistance could be ascertained in blood. We started by determining the mutational status of the RAS pathway in ctDNA using the approach described above. As expected, KRAS mutations were absent in the entire cohort. Two subjects (MOLI-CRC02 and MOLI-CRC06) displayed NRAS mutations ( Table 1 and  Supplementary Table 3) . Scrutiny of the clinical history of these individuals revealed that anti-EGFR treatment had been initiated before the introduction of NRAS testing in this clinical setting 2 .
We next sought to systematically identify genetic mechanisms of primary resistance to anti-EGFR treatment in the eight subjects in which the 'RAS pathway' was confirmed in plasma as being wild type. To this aim, we analyzed the coding region of 226 genes, which we selected as being involved in CRC progression, oncogenic signaling and sensitivity or resistance to therapy (Supplementary Table 4 ). The approach relies on massively parallel next-generation sequencing (NGS) of genomic DNA, which we adapted to capture and sequence ctDNA. To confirm that the NGS blood analysis could identify tumorexclusive (somatic) genetic alterations, we determined the mutational status of APC and TP53, two genes that are frequently mutated in CRC 23 . The analysis identified APC and/or TP53 mutations in circulating DNA that were not present in the germline DNA (Supplementary Table 5) .
Four cases (ONCGH-CRC01, ONCGH-CRC11, ONCGH-CRC06 and MOLI-CRC15) harbored ERBB2 amplification ( Table 1 and  Supplementary Table 3b ). We previously reported that ERBB2 amplification is present in approximately 3% of CRC samples and correlates with a lack of response to EGFR blockade 5 . These findings therefore validated the NGS-based experimental approach and increased our confidence in profiling plasma DNA to nominate molecular mechanisms of drug resistance. One of the ERBB2-positive samples also harbored FLT3 amplification; the latter has been previously detected in 3% of CRC samples [24] [25] [26] . In one subject (ONCG-CRC13) we detected a somatic variant of the MAP2K1 gene (p.K57N) encoding the MEK1 protein ( Table 1 and Supplementary Table 3a) . MAP2K1 mutations are present in 1.5% of colorectal tumors [24] [25] [26] , but they have not yet been associated with resistance to EGFR blockade. npg l e t t e r S nature medicine VOLUME 21 | NUMBER 7 | JULY 2015
We next asked whether analysis of plasma DNA could be used to unveil mechanisms of acquired (secondary) resistance to cetuximab or panitumumab. To answer this question, we studied the blood of 16 patients who initially responded to treatment and then showed disease progression on anti-EGFR therapy ( Table 1 and Supplementary  Table 3 ). We and others previously reported that acquired resistance to EGFR-specific antibodies is associated with the emergence of RAS pathway mutations, and that these mutations can be detected in the blood before disease progression is clinically manifest 16, [27] [28] [29] . Accordingly, in most of the individuals we studied (11/16), mutated KRAS alleles were detected in blood samples obtained at disease progression ( Table 1 and Supplementary Table 3a) . We also detected EGFR ectodomain mutations (in 2 cases) and KRAS or MET gene amplification in four instances ( Table 1 and Supplementary Table 3b ). We previously reported that amplification of KRAS and MET genes, as well as mutations in the extracellular domain of EGFR, sustain resistance to EGFR-specific antibodies in individuals with CRC 4, [29] [30] [31] .
The clinical management of individuals who develop resistance to EGFR blockade through emerging RAS pathway mutations remains challenging. Generally these individuals receive additional lines of therapy involving chemotherapeutic agents administered alone or in combination with anti-angiogenic drugs, and in some cases they receive further monotherapy with the multikinase inhibitor regorafenib. It is unknown whether subsequent therapies affect RAS clones, which are selected during treatment with EGFR-specific antibodies.
To address this issue, we monitored KRAS mutations and MET amplification during therapeutic schemes that are commonly administered at relapse after anti-EGFR treatment. We tracked resistant clones in the blood of individuals who initially benefited from and then experienced disease progression after treatment with an EGFRspecific antibody. For five subjects who developed KRAS mutations and for one subject who acquired MET amplification, samples were taken at baseline (before initiation of therapy), at the time of first disease progression and at different time points across subsequent lines of treatment ( Fig. 1 and Supplementary Table 6a) .
The analysis revealed that the percentage of mutated KRAS alleles, which emerge at the time of disease progression, declines when treatment with EGFR-specific antibodies is suspended and remains below the limit of detection across subsequent lines of treatment ( Fig. 1) . These findings led us to postulate that clonal evolution of tumor cell populations that survive treatment with EGFR-specific antibodies continues beyond the point of clinically established resistance.
To mechanistically evaluate this possibility, we studied populations of CRC cells (DiFi) in which acquisition of resistance to cetuximab is accompanied by amplification of the KRAS gene 15 . To parallel withdrawal of EGFR blockade, which occurs when patients develop cetuximab resistance, two populations of resistant DiFi cells were cultured for 160 d in the absence of anti-EGFR antibody (Fig. 2a) . Analogously to what we had observed in the blood of patients, KRAS copies declined significantly in both cell models (Student's t-test, P ≤ 0.01) when the EGFR-specific antibody was suspended ( Figs. 1 and 2) . The cell populations that experienced antibody withdrawal regained partial sensitivity to cetuximab (Student's t-test P ≤ 0.001), as compared to the population in which the drug pressure was maintained ( Fig. 2a  and Supplementary Fig. 2) .
The decline in altered KRAS alleles (both mutation frequency and copy number) we observed in blood upon withdrawal of EGFR blockade, as well as in our cell-based functional experiments suggests that re-challenge therapies may offer some benefit for CRC patients who, upon relapse, suspend the use of EGFR-targeted agents.
Scrutiny of our clinical databases revealed two subjects who responded to EGFR-specific antibodies and, upon relapse, received additional lines of therapy before again receiving EGFR-specific treatment with cetuximab or panitumumab (Fig. 2b,c) . Notably, re-challenge with EGFR blockade was clinically effective and triggered partial responses or long-lasting stabilization (Fig. 2b,c) . This is consistent with previous clinical data showing that CRC patients can respond to anti-EGFR re-challenge 32 .
We next asked whether intermittent treatment with EGFR-specific antibodies affected the genomic status of CRCs. To address this question, we studied three additional individuals who received multiple rounds of EGFR-specific antibodies and for whom longitudinal tissue or plasma samples were available (Fig. 3) .
In the first patient (HMAR-CRC08), tumor tissue was available before the first administration of anti-EGFR treatment, as well as at progression after a partial response of nearly 8 months. KRAS p.G12V was detected at resistance, and the percentage of mutated alleles declined when treatment with cetuximab plus irinotecan was suspended, as assessed by plasma analysis (Fig. 3a) . The subject then received standard chemotherapy, and when a new progression was detected, was re-challenged with cetuximab alone; this again resulted in a partial response, which lasted 18 months.
In the second individual (ONCG-CRC69), clonal tracking revealed that during the first round of EGFR blockade with cetuximab, a KRAS p.G13D-mutated clone arose in blood, and the allelic percentage declined when treatment was suspended owing to the patient refusing further therapy ( Fig. 3b and Supplementary Table 6b) . Subsequently, at disease progression, the subject received panitumumab, achieving stable disease with tumor shrinkage, which lasted for nearly 6 months (Fig. 3b) . Notably, during the second round of EGFR blockade, the percentage of KRAS p.G13D alleles increased again in blood and was accompanied by the emergence of another KRAS-mutant clone (p.G12V).
The third individual (AOUP-CRC05) developed a KRAS p.G12D clonal variant during the initial challenge with panitumumab, which resulted in a partial response. Upon disease progression, the patient received several salvage therapies, during which we collected a single plasma sample that again displayed a decline in the percentage of the mutated KRAS alleles that had emerged during the initial EGFR blockade. More than 1 year from the initial response to the EGFRspecific antibody the patient was treated again with panitumumab, achieving a partial response. During panitumumab re-challenge the percentage of KRAS p.G12D increased once more in plasma ( Fig. 3c and Supplementary Table 6 ).
The pulsatile behavior of KRAS clones detected in blood and cell lines suggests that colorectal cancers treated with EGFR-specific antibodies display remarkable plasticity. This is likely to reflect dynamic clonal competition, and it provides molecular evidence that re-challenge with EGFR blockade after a withdrawal period is effective, as it exerts genomic selection in metastatic CRCs (mCRCs).
Currently, individuals with CRC are treated according to mutational landscapes ascertained using a small fragment of the primary tumor or an individual metastatic lesion. Essentially, a single molecular snapshot is taken for each patient, and on the basis of this knowledge, several rounds of therapy are administered, often over many years. Rather than being based on out-of-date molecular pictures, each round of therapy should ideally be instituted on the basis of a recent genetic profile that is as comprehensive as possible with respect to the overall disease.
In this work we evaluated whether ctDNA can be used throughout the clinical management of CRC patients to gather real-time updates on npg l e t t e r S the molecular landscape of the disease. We find that mutational profiles determined in blood and tissues are highly concordant. In a relevant fraction of the cases (8%), analysis of circulating DNA identified KRAS or NRAS mutated alleles that were not detected in the corresponding tissue samples, thereby underscoring the ability of liquid biopsies to capture the heterogeneity of the overall disease. Our findings suggest that blood-based tests may more comprehensively interrogate the RAS pathway mutational status than tissue-derived genotypes. Only a small fraction (20%) of subjects who receive anti-EGFR therapies benefit from treatment. The molecular bases of the lack of response in the remaining patients are largely unknown. We find that ctDNA analyses can often identify genetic alterations that are likely to be responsible for resistance to EGFR blockade, including amplification of the ERBB2 and MET genes or mutations in MAP2K1. We also observe that CRC patients who do not carry RAS pathway mutations and whose disease is refractory to EGFR-specific antibodies frequently display clinically actionable oncogenic events. This approach may therefore be used to rapidly identify rare populations of patients who are likely to respond to targeted agents.
In accordance with our previous findings and other reports, mutated KRAS or NRAS clones often emerge in the blood of CRC patients who respond to cetuximab or panitumumab therapies 15, [33] [34] [35] . At present, these individuals discontinue treatment with EGFRspecific antibodies and receive salvage therapies based mainly on for approximately 6 months. At progression, the patient received capecitabine plus oxaliplatin (Xelox) with further progression of the disease after 3 months. The patient was subsequently re-treated with irinotecan plus cetuximab, achieving a partial response (PR). Gray area represents tumor load (percentage of baseline, calculated as described in Fig. 1 legend) ; dotted blue line indicates CEA (carcinoembryonic antigen) values. (c) Clinical synopsis of mCRC patient ONCG-CRC74, who was treated with cetuximab as a third-line therapy, achieving a partial response that lasted 13 months; the patient then refused further therapy because of skin toxicity. At disease progression, the subject underwent radiotherapy and treatment with 5-fluorouracil (5-FU) with PR until progression occurred after 6 months. The patient was re-challenged with anti-EGFR treatment, achieving long-lasting stable disease (7 months). Gray area represents tumor load (percentage of baseline, calculated as described in Fig 1 legend) ; dotted blue line indicates CEA values. Cetux, cetuximab.
npg l e t t e r S 8 0 0 VOLUME 21 | NUMBER 7 | JULY 2015 nature medicine chemotherapeutic agents. We discovered that the percentage of mutated KRAS clones declines in blood when EGFR-specific antibodies are withdrawn, suggesting that resistant cell populations are highly dynamic. To functionally substantiate these discoveries, we examined preclinical models of acquired resistance to cetuximab. Analogously to what we observed in patients, we noted that KRAS clones decay in drug-resistant populations upon antibody withdrawal. These results, together with the clinical cases in which we documented effectiveness of re-challenge with EGFR-specific antibodies paralleled by increasing and decreasing percentages of mutated KRAS clones, provide the rationale for adaptive therapy strategies. In this regard, discontinuous dosing strategy with BRAF inhibitors has been successfully attempted in preclinical models of BRAFdriven melanomas 36 . Furthermore, there is evidence that re-challenge with targeted therapies can be effective in subjects with different tumors types 32, [37] [38] [39] .
Our data suggests that further study should assess whether CRC cells that develop resistance to EGFR may display a fitness disadvantage in the absence of the drug, and whether this can be exploited to forestall the onset of lethal drug-resistant disease. Drug schedules, aimed at maintaining a stable population of drug-sensitive cells to suppress the growth of resistant clones through intratumoral competition, could be explored in ad hoc clinical trials. Accordingly, we plan to investigate the re-introduction of EGFR-specific antibodies in patients who achieve benefit from cetuximab or panitumumab and subsequently display a decline in the percentage of mutated KRAS clones in ctDNA.
In conclusion, our data indicate that blood, rather than tissue, can be used to closely monitor the molecular evolution of metastatic colorectal tumors. The finding that the genome of CRC adapts dynamically to pulsatile drug schedules provides a rationale for additional lines of therapy for individuals who benefit from an initial challenge with EGFR-specific antibodies.
METhoDs
Methods and any associated references are available in the online version of the paper. Figure 3 Mutated KRAS mutant clones dynamically evolve in response to pulsatile EGFR-specific antibody therapy. Dynamics of KRAS mutant clones in plasma samples of mCRC patients HMAR-CRC08 (a), ONCG-CRC69 (b) and AOUP-CRC05 (c), with each receiving the indicated therapies. Gray bars represent variation of tumor load, compared to baseline, during treatments as specified below the graphs. Tumor load was calculated as described in Figure 1 ) . Availability of tumor sample qualitatively and quantitatively suitable for molecular analyses was a requirement for being considered in the present study. The study was conducted according to the provisions of the Declaration of Helsinki, and all patients signed and provided their informed consent before sample collection. Disease extension and response were assessed by CT scans and clinical response was evaluated according to RECIST 1.1 criteria 40 . Two independent oncologists and radiologists verified in a blinded manner the clinical response for all patients. For a subset of the patients, plasma samples were also collected at selected time points (baseline, during EGFR-targeted therapy with cetuximab or panitumumab, at progression and during subsequent lines of treatment).
Mutational analysis of tissue specimens. Mutation analysis in tissue (primary tumor or metastasis) was carried out in the context of the standard management care of patients with mCRC considered for anti-EGFR treatment by the Institutions that participated in the study. The methodologies used in the study to determine mutations in tissue samples include High-resolution melting analysis (HMRA), Pyrosequencing and Sanger sequencing. These analyses were performed in pathology laboratories under diagnostic guidelines [41] [42] [43] [44] . The sensitivity for mutations detection across all platforms was at least 15%.
Plasma sample collection. At least 10 ml of whole blood was collected by blood draw using EDTA as anticoagulant. Plasma was separated within 5 h through two different centrifugation steps (the first at room temperature for 10 min at 1,600g and the second at 3,000g for the same time and temperature), obtaining up to 3 ml of plasma. Plasma was stored at −80 °C until ctDNA extraction.
ctDNA isolation and genome equivalents quantification (GE/ml plasma) and CEA assessment. ctDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions. We used 6 µl of ctDNA as template for each reaction. All samples were analyzed in triplicate. PCR reactions were performed using a 10-µl final volume containing 5 µl of GoTaq qPCR Master Mix, 2× with CXR reference dye) (Promega) and LINE-1 [12.5 µmol] forward and reverse primers. DNA at known concentrations was also used to build the standard curve. Primer sequences are available upon request.
CEA levels were assessed by Cobas 8000 modular analyzer system immunoassay (Roche Diagnostics).
BEAMing. BEAMing was performed as described previously 15, 33 , with further optimizations done in our laboratory. Primers and probes sequences are available upon request.
Droplet Digital PCR analysis. Isolated circulating free DNA was amplified using ddPCR Supermix for Probes (Bio-Rad) using KRAS, NRAS, BRAF (PrimePCR ddPCR Mutation Assay, Bio-Rad), EGFR (custom designed) ddPCR assays for point mutations and KRAS, MET and EIF2C1 (reference) for gene copy number variations (PrimePCR ddPCR Copy Number Assay, Bio-Rad). ddPCR was then performed according to manufacturer's protocol, and the results were reported as the percentage or fractional abundance of mutant DNA alleles to total (mutant plus wild-type) DNA alleles. 8-10 µl of DNA template was added to 10 µl of ddPCR Supermix for Probes (Bio-Rad) and 2 µl of the primer and probe mixture. This reaction mix was added to a DG8 cartridge together with 60 µl of Droplet Generation Oil for Probes (Bio-Rad) and used for droplet generation. Droplets were then transferred to a 96-well plate (Eppendorf) and then thermal cycled with the following conditions: 5 min at 95 °C, 40 cycles of 94 °C for 30 s, 55 °C for 1 min followed by 98 °C for 10 min (Ramp Rate 2 °C/s). Droplets were analyzed with the QX200 Droplet Reader (Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was performed based on positive and negative controls, and mutant populations were identified. The ddPCR data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain fractional abundance and copy number variations of the mutated or amplified DNA alleles in the wild-type or normal background. The quantification of the target molecule was presented as number of total copies (mutant plus WT) per sample in each reaction. Fractional Abundance is calculated as follows: F.A. % = (N mut /(N mut + N wt )) × 100), where N mut is the number of mutant events and N wt is the number of WT events per reaction. The number of positive and negative droplets is used to calculate the concentration of the target and reference DNA sequences and their Poisson-based 95% confidence intervals, as previously shown 45 . ddPCR analysis of normal control plasma DNA (from cell lines) and no DNA template controls were always included. Samples with too low positive events were repeated at least twice in independent experiments to validate the obtained results.
Next-generation sequencing analysis. Libraries were prepared with Nextera Rapid Capture Custom Enrichment Kit (Illumina Inc., San Diego, CA, USA), according to the manufacturer's protocol. Preparation of libraries was performed starting from up to 10-150 ng of plasma ctDNA and 50-100 ng of gDNA from PBMCs (as corresponding normal reference, or hg19 when germline DNA from the patient was not available). gDNA was fragmented using transposons, adding simultaneously adaptor sequences. For ctDNA libraries preparation we used the NEBNext Ultra DNA Library Prep Kit for Illumina (New England BioLabs Inc., Ipswich MA). Purified tagmented gDNA and ctDNA was used as template for subsequent PCR to introduce unique sample barcodes. DNA fragment size distribution was assessed using the 2100 Bioanalyzer with a High-Sensitivity DNA assay kit (Agilent Technologies, Santa Clara, CA). Equal amount of DNA libraries were pooled and subjected to targeted panel hybridization capture. Libraries were then sequenced using Illumina MiSeq or NextSeq500 sequencer (Illumina Inc., San Diego, CA, USA).
Bioinformatic analysis. We developed a bioinformatic pipeline for NGS data analysis to compare normal and tumor samples and to identify three kinds of variations: somatic mutations, insertions or deletions (indels) and gene copy number alterations. To this end, we combined open-source tools and custom scripts into a complete analysis workflow. Initially, FastQ sequences files generated by an Illumina sequencer for each sample were mapped to the human reference genome (assembly version hg19) using BWA mapper version 0.7.6 (ref. 46 ) with default parameters. The reads' alignment was saved as BAM files; these were subsequently sorted depending on their mapping position with the "sort" command in the software package SAMtools version 0. 1.19 (ref. 47) . PCR duplicates were removed from BAM files using the command "rmdup" of the SAMtools package. By using the "mpileup" command output, we calculated the alleles' counts using a custom script: for each position in the chromosome, we compared normal and tumor samples allele by allele. Somatic variations were then called only when supported by a 5% significance level obtained with a Fisher's Test. Mutations were annotated by a custom script printing out gene information, number of normal or mutated reads, the allelic frequencies and the variation effect (synonymous, nonsynonymous, stop-loss and gain). Each of these entries was associated with the corresponding number of occurrences in the COSMIC database 48 , the world′s largest resource for exploring the impact of somatic mutations in human cancer. To identify indels, we further analyzed the alignment files by comparing normal versus tumor samples using Pindel software 49 with human genome as reference. 
